COST OF RESISTANCE

Coast J, Smith RD, Millar MR. 1998. An economic perspective on policy to reduce antimicrobial resistance. Social Science and Medicine46(1):29–38.


Phillips M, Phillips-Howard PA. 1996. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics10(3):225–238.


Smith RD, Coast J, Millar MR. 1996. Over-the-counter antimicrobials: the hidden costs of resistance. Journal of Antimicrobial Chemotherapy37(5):1031–1032.

BACTERIAL RESISTANCE

Arnadottir T. 2001. Tuberculosis: trends and the twenty-first century. Scandinavian Journal of Infectious Diseases33(8):563–567.


Banatvala N, Peremitin GG. 1999. Tuberculosis, Russia, and the Holy Grail. Lancet 353(9157):999–1000.


Diwan VK, Thorson A. 1999. Sex, gender, and tuberculosis. Lancet353(9157):1000–1001.


Gleissberg V. 1999. The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?Lancet353(9157):998–999.


McCormick JB. 1998. Epidemiology of emerging/re-emerging antimicrobial-resistant bacterial pathogens. Current Opinion in Microbiology1(1):125–129.

McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, Hakenbeck R, Hryniewicz W, Lefevre JC, Tomasz A, Klugman KP. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. Journal of Clinical Microbiology39(7):2565–2571. Available at: http://jcm.asm.org/cgi/content/full/39/7/2565?view=full&pmid=11427569.


Pinho MG, Filipe SR, de Lencastre H, Tomasz A. 2001. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. Journal of Bacteriology 183(22):6525–6531. Available at: http://jb.asm.org/cgi/content/full/183/22/6525?view=full&pmid=11673420.


Somoskovi A, Parsons LM, Salfinger M. 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Research 2(3):164–168. Available at: http://respiratory-research.com/content/2/3/164.


World Health Organization. 2000.Anti-Tuberculosis Drug Resistance in the World. Report No. 2: Prevalence and Trends. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug-Resistance Surveillance. Available at: http://www.who.int/gtb/publications/dritw/index.htm.

VIRAL RESISTANCE

Blower SM, Porco TC, Darby G. 1998. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Medicine4(6):673–678.


Gumina G, Song GY, Chu CK. 2001. Advances in antiviral agents for hepatitis B virus. Antiviral Chemistry and Chemotherapy12 Suppl 1:93–117.


Mital D, Pillay D. 2001. The impact of HIV-1 subtype on drug resistance. Journal of HIV Therapy6(3):56–60.


Pineo GF, Hull RD. 2001. Dalteparin sodium. Expert Opinion on Pharmacotherapy 2(8):1325–1337.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement